Dr. Alejandro D. Jorrin, MD
Internal Medicine (Internal Medicine Physician)
At a glance
- In the NPI registry since
- 2009
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
FL license ME113972 -
Cardiovascular Disease Physician
FL license ME113972
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 1 companies reported 16 payments worth $11,458 in total to this clinician.
| Eli Lilly and Company | $11,458 |
|---|
| Food and Beverage | $10,004 |
|---|---|
| Travel and Lodging | $1,454 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $332 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $269 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $269 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $179 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $179 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $90.00 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $46.06 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $45.73 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $13.92 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $13.92 |
All 15 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $332 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $269 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $269 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $179 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $179 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $90.00 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $46.06 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $45.73 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $13.92 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $13.92 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $6.96 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $2.99 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $2.99 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $1.99 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $1.49 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $464,654 in research payments for these studies, mostly to the institutions running them.
- A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Eli Lilly and Company · Active, not recruiting · NCT06859268 - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
ModernaTX, Inc. · Terminated · NCT05085366 - Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Sun Pharmaceutical Industries Inc. - A phase 3B, randomized, double-blinded, placebo- controlled study to evaluate retatrutide treatment in the maintenance of weight reduction in individuals with obesity (TRIUMPH-6)
Eli Lilly and Company
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.